The FDA has approved Fabhalta (iptacopan) for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

Secondary rectal cancer tumors that develop years after prostate cancer radiation therapy appear to differ in distinct ways from primary rectal cancers.

Clinicians should not neglect proteinuria testing in adults younger than age 40 years to identify those at high risk for sudden cardiac arrest.

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection), a radioactive diagnostic agent for prostate cancer detection.

(HealthDay News) — Subclinical cardiac dysfunction is associated with brain imaging markers of neurodegeneration, according to a study published online March 26 in Neurology.

GAGome score had 90 percent sensitivity, 51 percent specificity for radiological recurrence, with AUC of 0.73 for nonmetastatic clear-cell renal cell carcinoma.

(HealthDay News) — Colorectal cancer (CRC) is tied to an increased risk for cardiovascular mortality, especially in individuals younger than 50 years, according to a study presented at the annual ...

Atrasentan reduced urine protein-to-creatinine ratio by 38% compared with 3% for placebo at week 36. The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ...

The pair take on their new roles in the wake of mass firings — and subsequent rehirings — at the NIH and FDA, with the threat of additional layoffs looming. The Senate has confirmed new ...

Maintaining systolic blood pressure consistently below 130 mmHg could help decrease the risk for new-onset diabetes in the ...